BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI)

Q1 2015 13F Holders as of 31 Mar 2015

Type / Class
Equity / COM NEW
Total 13F shares
2,407,922
Share change
+2,305,296
Total reported value
$10,712,000
Price per share
$4.45
Number of holders
20
Value change
+$10,257,636
Number of buys
16
Number of sells
2

Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q1 2015

As of 31 Mar 2015, BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by 20 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,407,922 shares. The largest 10 holders included SABBY MANAGEMENT, LLC, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Spark Investment Management LLC, TFS CAPITAL LLC, M&T BANK CORP, NORTHERN TRUST CORP, Bank of New York Mellon Corp, and HighTower Advisors, LLC. This page lists 20 institutional shareholders reporting positions in this security for the Q1 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.